(Q37309885)

English

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

scientific article published on January 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol (English)

1 reference

Europe PubMed Central

19 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Alm A

1

1 reference

Europe PubMed Central

19 August 2017

Widengård I

2

1 reference

Europe PubMed Central

19 August 2017

Kjellgren D

3

1 reference

Europe PubMed Central

19 August 2017

Söderström M

4

1 reference

Europe PubMed Central

19 August 2017

Friström B

5

1 reference

Europe PubMed Central

19 August 2017

Heijl A

6

1 reference

Europe PubMed Central

19 August 2017

Stjerschantz J

7

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

1 January 1995

1 reference

Europe PubMed Central

19 August 2017

British Journal of Ophthalmology

1 reference

Europe PubMed Central

19 August 2017

79

1 reference

Europe PubMed Central

19 August 2017

1

1 reference

Europe PubMed Central

19 August 2017

12-16

1 reference

Europe PubMed Central

19 August 2017

Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505011

6 September 2017

PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505011

6 September 2017

Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505011

26 June 2018

Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505011

26 June 2018

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505011

26 June 2018

The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505011

26 June 2018

Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505011

26 June 2018

Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of prostaglandin F2 alpha on trabecular outflow facility in cynomolgus monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://pubmed.ncbi.nlm.nih.gov/7880782

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BJO.79.1.12

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37309885&oldid=1700071705"